Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company is headquartered in Waltham, Massachusetts. Show more

Location: 300 Fifth Avenue, Waltham, MA, 02451, United States | Website: https://crescentbiopharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

252.6M

52 Wk Range

$9.81 - $37.00

Previous Close

$15.08

Open

$15.03

Volume

9,609

Day Range

$14.82 - $15.32

Enterprise Value

125.6M

Cash

133.3M

Avg Qtr Burn

-6.269M

Insider Ownership

10.37%

Institutional Own.

81.62%

Qtr Updated

09/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CR-001 Details Solid tumor/s	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SQ Dalcinonacog alfa (DalcA) Details Hemophilia, Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Marzeptacog alfa (MarzAA) Details Hemophilia, Blood disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.